Gynaecological Cancers

Select a discussion in the hub to watch our multidisciplinary team share expert perspectives on the appropriate implementation of immune checkpoint inhibitors through shared decision making to ensure optimal outcomes for patients with endometrial cancer.

Watch three experts discuss the importance of HPV vaccination in preventing HPV-associated cancers, and how to maximize vaccine uptake

This July, the PrEvCan campaign is dedicated to raising awareness about women’s cancer risk in connection with breastfeeding and hormone replacement therapy (HRT).  Initiated by the European Oncology Nursing Society (EONS), and with ESMO as a key campaign partner, the PrEvCan – Cancer Prevention Across Europe – campaign, is aimed at reducing the burden of […]

The relationship between breastfeeding and a reduction in cancer risk is the focus of the PrEvCan Campaign, this July.  Initiated by the European Oncology Nursing Society (EONS), and with ESMO as a key campaign partner, the PrEvCan – Cancer Prevention Across Europe – campaign, is aimed at reducing the burden of cancer.  In this interview […]

Watch this activity exploring recent developments on the use of PARP inhibitors in ovarian cancer, covering first-line maintenance therapy, selection and sequencing implications, and future directions including emerging neoadjuvant and combination regimens. Filmed following the SGO Annual Meeting 2023.

Watch this two-part activity exploring the latest data on the use of PARP inhibitors in first-line maintenance therapy in ovarian cancer. Filmed following the ESGO European Congress on Gynaecological Oncology 2022. Part 1: Watch gynaecological cancer expert Prof. Jonathan Ledermann review key data from ESGO 2022 Watch Now Part 2: Watch leading experts consider what these data may mean for global and regional practice Select An Interview

The Phase III SOLO1/GOG-3004 trial (NCT01844986), investigated maintenance olaparib, which provided sustained benefit beyond the end of treatment in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Prof. Paul DiSilvestro (Brown University, Providence, RI, USA) joins touchONCOLOGY to discuss the efficacy and safety of maintenance olaparib, and overall survival findings at 7 years. […]

Maintenance chemotherapy with oral tegafur-uracil (UFT) after surgery has been shown to prolong survival in lung, breast, gastric and colon cancer. Dr Keiichi Fujiwara (Saitama Medical University International Medical Centre, Saitama, Japan) joins touchONCOLOGY to discuss the phase 3 GOTIC-002 LUFT study results, investigating the efficacy of maintenance chemotherapy using UFT following concurrent chemoradiotherapy for […]

Dr Keiichi Fujiwara joins touchONCOLOGY to discuss his thoughts on the latest clinical trial highlights at European Society for Medical Oncology (ESMO) 2022 in gynaecological cancers, specifically the GOTIC-002 LUFT study. Watch Dr Keiichi Fujiwara’s interview at ESMO 2022, on the Phase 3 GOTIC-002 LUFT study results – chemotherapy with tegafur-uracil for locally advanced cervical […]